News
News
 |
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 19, 2023Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...
- Sep 14, 2023
Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
- Sep 6, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar event. CAMBRIDGE, Mass., Sept. 6, 2023...
- Aug 16, 2023
ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023...
-
Jul 17, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023...
